title: MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice.
abstract: Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.
authors.affiliation: Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, 50009 Zaragoza, Spain; CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Nacho
authors.initials: N
authors.lastname: Aguilo
authors.affiliation: Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, 50009 Zaragoza, Spain; CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: Uranga
authors.affiliation: Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, 50009 Zaragoza, Spain; CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Dessislava
authors.initials: D
authors.lastname: Marinova
authors.affiliation: Research Centre for Encephalopathies and Transmissible Emerging Diseases, Universidad de Zaragoza, 50013 Zaragoza, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Monzon
authors.affiliation: Research Centre for Encephalopathies and Transmissible Emerging Diseases, Universidad de Zaragoza, 50013 Zaragoza, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Badiola
authors.affiliation: Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, 50009 Zaragoza, Spain; CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Servicio de Microbiología, Hospital Universitario Miguel Servet, ISS Aragón, 50009 Zaragoza, Spain. Electronic address: carlos@unizar.es.
authors.forename: Carlos
authors.initials: C
authors.lastname: Martin
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001500:BCG Vaccine / Q000276:immunology / Q000494:pharmacology; D004195:Disease Models, Animal; D007371:Interferon-gamma / Q000276:immunology / Q000378:metabolism; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000254:growth & development*; D013154:Spleen / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013997:Time Factors; D014376:Tuberculosis / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology / Q000494:pharmacology* / Q000633:toxicity; D015430:Weight Gain
chemical_list: D001500:BCG Vaccine; C000611740:MTBVAC vaccine; D032581:Tuberculosis Vaccines; D007371:Interferon-gamma
keywords: MTBVAC; Neonates; Newborn mice; Tuberculosis vaccine